A Randomimized, double blind, Parallel group study to assess safety and efficacy of Magnesium Glycinate in the management of selected inflammatory disease like Asthma, COPD, Rheumatoid Arthritis and Osteoarthritis

The study titled "Efficacy and Safety of Magnesium Glycinate as an Add-On Therapy in the Management of Selected Inflammatory Disorders" investigates the potential benefits of magnesium glycinate as an adjunct treatment for chronic inflammatory conditions such as asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), and osteoarthritis (OA). Conducted under the supervision of Dr. M.G. Rajanandh and presented by Maddirevula Maneesh Kumar Reddy, the research explores the hypothesis that magnesium supplementation can reduce inflammation and improve patient outcomes.

Background and RationaleMagnesium deficiency is linked to increased inflammation due to various biological mechanisms, including activation of immune cells and inflammatory pathways. Chronic inflammatory conditions like asthma, COPD, RA, and OA are exacerbated by such deficiencies. Traditional anti-inflammatory medications often lead to severe side effects, emphasizing the need for safer alternatives. Magnesium, crucial for numerous enzymatic processes, nerve function, heart health, and immune response, is a promising candidate due to its role in reducing systemic inflammation.